
Brian J. Forsatz Ph.D. Of Counsel

bforsatz@gibsondunn.com

T: +1 212.351.2488

New York



Dr. Forsatz advises clients on complex life sciences patent litigations as well as related regulatory, antitrust, and trade secret issues. He has extensive experience in Hatch-Waxman litigation having counseled numerous biotechnology and pharmaceutical companies in developing effective patent litigation strategies for a wide array of products. Specifically, Dr. Forsatz has lead patent litigations involving small molecule drugs, biological products, medical devices, and laboratory analytical instruments.

Dr. Forsatz has been named a "Rising Star" three times by *Super Lawyers* (2021, 2022, and 2023). In 2021, *Patexia* recognized Dr. Forsatz as among the best performing and most active practitioners in the Hatch-Waxman litigation space since 2021.

Before joining Gibson Dunn, Dr. Forsatz was a litigation attorney at Quinn Emanuel Urquhart & Sullivan since 2013. For over a decade before that, Dr. Forsatz worked as a pharmaceutical research and development scientist. During his pharmaceutical career, he conducted original research and was responsible for several research groups that focused on products for a variety of medical conditions, including asthma, allergies, cardiovascular, anti-inflammation, hematology, and oncology. His practical industry experience is indispensable to clients who seek Dr. Forsatz's assessment as part of their intellectual property strategy.

Representative Experience*:

- Axsome Therapeutics, Inc.: Multiple Hatch-Waxman actions relating to Sunosi® (solriamfetol) drug product.
- Veloxis Pharmaceuticals, Inc.: Multiple Hatch-Waxman actions relating to Envarsus XR® (tacrolimus) drug products.
- Medytox, Inc.: ITC investigation related to botulinum toxin products.
- Jazz Pharmaceuticals, Inc.: Brand versus brand patent infringement and trade secret matters.
- Takeda Pharmaceuticals, Inc.: Multiple Hatch-Waxman actions relating to Iclusig® (ponatinib) drug product.
- Celgene Corporation: More than a dozen Hatch-Waxman actions relating to Revlimid® (lenalidomide) drug products.
- Janssen Pharmaceuticals, Inc. and Mitsubishi Tanabe Pharma: More than a dozen Hatch-Waxman actions relating to Invokana® (canagliflozin)/Invokamet®/Invokamet XR® drug products.
- Celgene Corporation: Multiple Hatch-Waxman actions related to Pomalyst® (pomalidomide) drug products.



Capabilities

Intellectual Property
Antitrust and Competition
Life Sciences
Litigation

Credentials

Education

Fordham University - 2013 Juris Doctor Seton Hall University - 2007 Doctor of Philosophy

Rutgers University - 1999 Bachelor of Science

Admissions

New York Bar New Jersey Bar Jazz Pharmaceuticals, Inc.: Multiple Hatch-Waxman actions relating to Xyrem® (sodium oxybate) drug product.

*Includes recent experience prior to joining Gibson Dunn.

Dr. Forsatz received his Juris Doctor from Fordham University School of Law. Before practicing law, Dr. Forsatz received a Ph.D. in chemistry from Seton Hall University and a B.S. in Biochemistry from Rutgers University.

Brian J. Forsatz Ph.D.

Of Counsel

bforsatz@gibsondunn.com

T: +1 212.351.2488

New York